Marinus Pharmaceuticals Inc (MRNS)
1.33
+0.03
(+2.31%)
USD |
NASDAQ |
May 17, 16:00
1.33
0.00 (0.00%)
After-Hours: 20:00
Marinus Pharmaceuticals Cash and Short Term Investments (Quarterly): 113.25M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 113.25M |
| December 31, 2023 | 150.29M |
| September 30, 2023 | 176.36M |
| June 30, 2023 | 175.34M |
| March 31, 2023 | 199.20M |
| December 31, 2022 | 240.55M |
| September 30, 2022 | 168.25M |
| June 30, 2022 | 92.33M |
| March 31, 2022 | 126.32M |
| December 31, 2021 | 122.93M |
| September 30, 2021 | 145.10M |
| June 30, 2021 | 112.49M |
| March 31, 2021 | 123.47M |
| December 31, 2020 | 139.98M |
| September 30, 2020 | 91.30M |
| June 30, 2020 | 105.90M |
| March 31, 2020 | 77.79M |
| December 31, 2019 | 91.68M |
| September 30, 2019 | 39.89M |
| June 30, 2019 | 51.92M |
| March 31, 2019 | 60.85M |
| Date | Value |
|---|---|
| December 31, 2018 | 72.72M |
| September 30, 2018 | 39.63M |
| June 30, 2018 | 46.37M |
| March 31, 2018 | 52.02M |
| December 31, 2017 | 53.39M |
| September 30, 2017 | 42.96M |
| June 30, 2017 | 20.28M |
| March 31, 2017 | 24.76M |
| December 31, 2016 | 30.10M |
| September 30, 2016 | 36.57M |
| June 30, 2016 | 44.02M |
| March 31, 2016 | 51.20M |
| December 31, 2015 | 56.20M |
| September 30, 2015 | 33.00M |
| June 30, 2015 | 39.93M |
| March 31, 2015 | 45.47M |
| December 31, 2014 | 49.72M |
| September 30, 2014 | 47.11M |
| June 30, 2014 | 8.416M |
| March 31, 2014 | 8.830M |
| December 31, 2013 | 10.04M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
39.89M
Minimum
Sep 2019
240.55M
Maximum
Dec 2022
127.22M
Average
123.20M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Pfizer Inc | 11.93B |
| ACADIA Pharmaceuticals Inc | 470.52M |
| Alnylam Pharmaceuticals Inc | 2.371B |
| Regeneron Pharmaceuticals Inc | 10.52B |
| Actinium Pharmaceuticals Inc | 84.06M |